Lee D.K.,Sahmyook University |
Park J.E.,Sahmyook University |
Kim M.J.,Sahmyook University |
Seo J.G.,Cellbiotech Co. |
And 2 more authors.
Clinics and Research in Hepatology and Gastroenterology
Background and objectives: Evidence suggests that specific probiotics may be antagonistic to enteric pathogens and enhance immunity, and thus, provide a means of preventing or treating diarrheal diseases. In the present study, we aimed to evaluate the efficacy of probiotic strains isolated from Koreans for the treatment of viral gastroenteritis in young children and against rotavirus in vitro. Methods: In vitro antiviral activities of probiotic isolates on rotavirus infection were investigated in the Vero cell using a plaque reduction assay. Then several probiotic strains with the high antiviral activity were chosen for further clinical trials. Twenty-nine pediatric patients who presented with symptoms of viral gastroenteritis were enrolled in a double-blind trial and randomly assigned at admission to receive six probiotic strains (Bifidobacterium longum, B.lactis, Lactobacillus acidophilus, L.rhamnosus, L.plantarum, and Pediococcus pentosaceus) at a dose of 109colony forming units/g or a comparable placebo twice daily for 1week. Results and conclusions: Of the tested probiotic strains, B. longum isolated from an infant showed the greatest inhibitory effect and L.. acidophilus showed the second-highest inhibitory effect. These probiotics significantly shortened the duration of diarrhea as compared with a placebo (6.1 ± 0.5 vs 7.2 ± 1.9, P=0.030) and did not induce any adverse effects. Our findings suggest that the probiotic strains selected in the present study may be useful for the treatment of acute rotaviral gastroenteritis or as an alternative therapy without adverse effects. © 2014 Elsevier Masson SAS. Source
Han K.,Dongguk University |
Wang J.,Dongguk University |
Seo J.-G.,Cellbiotech Co. |
Kim H.,Dongguk University
Journal of Gastroenterology
Background: The purpose of this study was to elucidate the effects of a dual-coated probiotic supplement (Duolac Care) on symptoms of diarrhea-predominant irritable bowel syndrome in a randomized double-blind clinical trial. Methods: Fifty subjects with diarrhea-predominant irritable bowel syndrome were randomly assigned to either the non-coating group or the dual-coating group in order to receive two capsules per day of multi-species probiotics containing 5 billion bacteria per capsule for 4 weeks. Data from an adequate relief questionnaire were used in assessment of primary outcome. Daily records of stool frequencies and the Bristol stool scale, a weekly symptom diary using 100-mm visual analog scale, and Beck depression inventories were collected. Blood tests including blood cell counts, interleukin-10, tumor necrosis factor-alpha and inducible nitric oxide synthase, and regulatory T cells—CD4 + CD25high T cells, CD4 + LAP + T cells and CD25high + LAP + T cells—were analyzed before and after the study. The shift of gut microbiota was investigated using a quantitative real-time polymerase chain reaction assay. Results: Responses to the adequate relief questionnaire indicated significant improvement in overall discomfort in the dual-coating group and the ratio of normal stools to hard or watery stools had a better effect from dual-coated probiotics compared to non-coated probiotics. This may be due to a shift of intestinal microbiota, as our correlation analysis showed significant negative correlation between Bifidobacterium and urgency of defecation. Conclusions: Our result implies that dual-coating layers of probiotic supplement can be a candidate for treatment of diarrhea-predominant irritable bowel syndrome. © 2016 Japanese Society of Gastroenterology Source
Nam Y.-D.,Kyung Hee University |
Nam Y.-D.,Korea Food Research Institute |
Kim H.J.,Seoul National University |
Seo J.-G.,Cellbiotech Co. |
And 2 more authors.
Although pelvic irradiation is effective for the treatment of various cancer types, many patients who receive radiotherapy experience serious complications. Gut microbial dysbiosis was hypothesized to be related to the occurrence of radiation-induced complications in cancer patients. Given the lack of clinical or experimental data on the impact of radiation on gut microbiota, a prospective observational study of gut microbiota was performed in gynecological cancer patients receiving pelvic radiotherapy. In the current study, the overall composition and alteration of gut microbiota in cancer patients receiving radiation were investigated by 454 pyrosequencing. Gut microbial composition showed significant differences (P < 0.001) between cancer patients and healthy individuals. The numbers of species-level taxa were severely reduced after radiotherapy (P < 0.045), and the abundance of each community largely changed. In particular, the phyla Firmicutes and Fusobacterium were significantly decreased by 10% and increased by 3% after radiation therapy, respectively. In addition, overall gut microbial composition was gradually remolded after the full treatment course of pelvic radiotherapy. In this set of cancer patients, dysbiosis of the gut microbiota was linked to health status, and the gut microbiota was influenced by pelvic radiotherapy. Although further studies are needed to elucidate the relationship between dysbiosis and complications induced by pelvic radiotherapy, the current study may offer insights into the treatment of cancer patients suffering from complications after radiation therapy. Copyright: © 2013 Nam et al. Source
Cell Biotech Co. | Date: 2013-06-05
Baby food made from livestock products; baby foods made from agricultural products; lacteal flour for babies; medicine for intestinal disorders; medicines for veterinary purposes namely, for treatment of intestinal bacteria; agents for immunity adjustment; milk ferments for pharmaceutical purposes; medicines for alleviating constipation; additives to fodder for medical purposes in the nature of dietary supplements; nutritional supplements for medical purposes; chewing gum for medical purposes; lactic acid bacteria capsules for medical purposes; lactic acid bacteria microorganisms for medical purposes; biological preparations for medical purposes for treatment of cancer, heart disease, and neurological diseases; all of the foregoing containing probiotics. Lactic acid bacteria drinks; lactic-acid fermented milk; yogurt; nutritional supplement containing lactic ferments; lactic-acid fermented cheese; lactic-acid fermented sausages; ham containing lactic ferments; lactic-acid fermented kimchi; all of the foregoing containing probiotics. Brown rice flour for food; frozen yogurt namely, confectionery ices; chewing gum; candy; mayonnaise; dressings for salad; ginseng tea; black tea; green tea; coffee-based beverages; lactic-acid fermented bread; all of the foregoing containing probiotics.
Cell Biotech Co. | Date: 2011-10-11
The present invention relates to multi-coated lactic acid bacteria coated with a multi-coating layer forming bacterial clusters and including protein, polysaccharide, and edible oil/fat component, and a preparing method thereof. The multi-coated lactic acid bacteria according to the present invention may achieve an improved acid resistance, a bile resistance, and an accelerated test stability, may have a low moisture content to be particularly stable against a moisture variation, and thus may be appropriately used to prepare various products including lactic acid bacteria.